Health Dictionary
Reliable, easy-to-read patient information on common medical conditions â written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Splenic marginal zone lymphoma surgery
Introduction
Overview
Overview
Splenectomy was considered to be the 1st line treatment option for splenic marginal zone lymphoma (SMZL) but recent studies have shown that rituximab is equally effective if not better treatment option in terms of overall survival. Splenectomy is still performed but mainly in patients with splenomegaly without lymphadenopathy having low surgical risk or in those who are refractory to rituximab therapy.
Surgery
Surgery
- Splenectomy has been performed for the treatment of splenic marginal zone lymphoma (SMZL) over the years with a good success rate and may be delayed until the patient become symptomatic or develop cytopenia.[1][2][3]
- Response to splenectomy is partial as lymphocytosis and bone marrow infiltration persists. but it still remains a useful option for treating splenic marginal zone lymphoma (SMZL) in symptomatic patients.[4][5][6]
- Splenectomy has been used alone as well as in combination with chemotherapy regime for the treatment and no difference of overall survival benefit was found between the two therapeutic modalities. But they are considered superior to the use of chemotherapy alone [7][8]
- There is perioperative risk associated with splenectomy.[9]
References
References
- â Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, Arcache J, Callet-Bauchu E, Salles G, Coiffier B (June 2002). “Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients”. Clin Lymphoma. 3 (1): 41â7. PMIDÂ 12141954.
- â Wu Z, Zhou J, Wang X, Li YB, Niu T, Peng B (June 2013). “Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma”. World J. Gastroenterol. 19 (24): 3854â60. doi:10.3748/wjg.v19.i24.3854. PMCÂ 3699034. PMIDÂ 23840125.
- â Matutes E (April 2007). “Splenic marginal zone lymphoma with and without villous lymphocytes”. Curr Treat Options Oncol. 8 (2): 109â16. doi:10.1007/s11864-007-0026-0. PMIDÂ 17680218.
- â Franco V, Florena AM, Stella M, Rizzo A, Iannitto E, Quintini G, Campesi G (January 2001). “Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes”. Cancer. 91 (2): 294â301. PMIDÂ 11180074.
- â Arcaini L, Rossi D, Paulli M (April 2016). “Splenic marginal zone lymphoma: from genetics to management”. Blood. 127 (17): 2072â81. doi:10.1182/blood-2015-11-624312. PMIDÂ 26989207.
- â Xing KH, Kahlon A, Skinnider BF, Connors JM, Gascoyne RD, Sehn LH, Savage KJ, Slack GW, Shenkier TN, Klasa R, Gerrie AS, Villa D (May 2015). “Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia”. Br. J. Haematol. 169 (4): 520â7. doi:10.1111/bjh.13320. PMIDÂ 25854936.
- â Milosevic R, Todorovic M, Balint B, Jevtic M, Krstic M, Ristanovic E, Antonijevic N, Pavlovic M, Perunicic M, Petrovic M, Mihaljevic B (August 2009). “Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma”. World J. Gastroenterol. 15 (32): 4009â15. PMCÂ 2731951. PMIDÂ 19705496.
- â Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D (March 2003). “Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients”. Br. J. Haematol. 120 (5): 759â64. PMIDÂ 12614206.
- â Kennedy ND, LĂŞ GN, Kelly ME, Harding T, Fadalla K, Winter DC (May 2018). “Surgical management of splenic marginal zone lymphoma”. Ir J Med Sci. 187 (2): 343â347. doi:10.1007/s11845-017-1689-6. PMIDÂ 29043543.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Muhammad Affan M.D.[2], Sowminya Arikapudi, M.B,B.S. [3]